Clinical evaluation of infliximab combined with bifidobacterium quadruple live bacteria in patients with ulcerative colitis
Ayguli Abramiti
Zhao Jin
Jin Yingchun
Liu Rongxi
Abstract：Objective To explore the efficacy of bifidobacterium quadruple viable bacteria combined with infliximab(IFX)in the treatment of ulcerative colitis(UC).Methods A total of 128 patients with UC who were treated in the Xinjiang Military Region General Hospital from January 2022 to January 2024,were divided into the IFX group(n=64,IFX regimen)and the combined group(n=64,IFX regimen combined with bifidobacterium quadruple viable bacteria)by drawing lots.The clinical efficacy,levels of T lym-phocyte subsets(CD3+,CD4+,CD8+,CD4+/CD8+),levels of inflammatory factors(tumor necrosis factor α(TNF-α),interleukin1β(IL-1β),interleukin-6(IL-6)),recovery duration of laboratory indexes,time of disappearance of clinical symptoms,and the total incidence rate of adverse reactions were compared between the two groups.Results The total clinical effective rate in the combined group was 89.07%(57/64),which was higher than that of the IFX group(75.00%(48/64))(χ2=4.293,P<0.05).After treatment,the CD3+lev-el((62.18±5.64)%vs(53.21±5.63)%),CD4+level((39.54±3.51)%vs(33.54±3.52)%)and CD4+/CD8+level((1.51±0.45)vs(1.16±0.45))in the combined group were higher than those in the IFX group while the CD8+level((26.15±7.84)%vs(29.01±7.83)%)was lower compared to the IFX group(t=9.005,9.656,4.400,2.065,P<0.05).The TNF-α((16.48±2.74)pg·mL-1 vs(20.45±2.78)pg·mL-1),IL-1β((47.51±5.54)pg·mL-1 vs(56.54±5.53)pg·mL-1)and IL-6((70.42±6.51)pg·mL-1 vs(81.51±6.53)pg·mL-1)in the combined group after treatment were lower than those in the IFX group(t=8.137,9.229,9.622,all P<0.05).In the combined group,the hematochezia disap-pearance time((11.53±2.14)d vs(14.54±2.18)d),diarrhea disappearance time((11.52±2.13)d vs(15.04±2.17)d),C-reactive protein normal recovery time((8.15±1.04)d vs(11.17±2.31)d),and normal recovery time of erythrocyte sedimentation rates((11.07±1.06)d vs(13.54±1.72)d)were shorter than those in the IFX group(t=7.883,9.239,9.537,9.780,P<0.05).No significant difference was exhib-ited in the total incidence rate of adverse reactions between the two groups(χ2=0.699,P>0.05).Conclusion IFX regimen combined with bifidobacterium quadruple viable bacteria for patients with UC can improve the clinical efficacy and immune function,reduce the inflammatory response,and shorten the recovery time,with high safety.
Keywords：InfliximabBifidobacterium quadruple viable bacteriaUlcerative colitisImmune functionInflammatory response
Publication Date：2025-08-25
Online Publishing Date：2025-09-01(First online date of this platform, not the publication date of the document)
Pages：4( 852-855 )